Description

IVERZOOM 12 MG

Indications

IVERZOOM 12 MG is primarily indicated for the treatment of various parasitic infections, particularly those caused by helminths and ectoparasites. It is commonly prescribed for conditions such as strongyloidiasis, onchocerciasis, and other infections caused by nematodes. The medication is also used in the management of certain dermatological conditions associated with parasitic infestations. The effectiveness of IVERZOOM in these indications has been well documented in clinical settings.

Mechanism of Action

The active ingredient in IVERZOOM is ivermectin, a broad-spectrum antiparasitic agent. Ivermectin works by binding to specific chloride channels in the nerve and muscle cells of parasites. This binding leads to an increase in permeability of the cell membranes to chloride ions, resulting in paralysis and death of the parasites. Additionally, IVERZOOM disrupts the function of the parasite’s nervous system and muscle function, which inhibits their ability to reproduce and survive. This dual mechanism makes IVERZOOM effective against a wide range of parasitic infections.

Pharmacological Properties

IVERZOOM is well absorbed in the gastrointestinal tract, with peak plasma concentrations typically reached within 4 hours of oral administration. The bioavailability of ivermectin is approximately 65% to 75%. The drug is extensively distributed throughout the body, with a volume of distribution of about 4 to 6 L/kg. IVERZOOM is metabolized in the liver, primarily by cytochrome P450 enzymes, and excreted mainly in the feces. The half-life of ivermectin is approximately 12 to 36 hours, allowing for once-daily dosing in many cases.

Contraindications

IVERZOOM should not be used in individuals who have a known hypersensitivity to ivermectin or any of the excipients in the formulation. It is contraindicated in patients with meningitis or other central nervous system disorders due to the potential for exacerbating these conditions. Additionally, caution should be exercised in patients with severe liver impairment, as this may affect drug metabolism and increase the risk of adverse effects.

Side Effects

Common side effects associated with IVERZOOM include dizziness, fatigue, headache, nausea, vomiting, diarrhea, and abdominal pain. These effects are generally mild and transient. However, more serious side effects may occur, such as allergic reactions, including rash, itching, or swelling. In rare cases, patients may experience neurological effects, including seizures or confusion, particularly in cases of excessive dosing or in individuals with compromised blood-brain barriers. Patients should be monitored for any unusual symptoms during treatment.

Dosage and Administration

The recommended dosage of IVERZOOM 12 MG varies depending on the specific parasitic infection being treated. For adults and children over 15 kg, a single oral dose of 150 to 200 micrograms per kilogram of body weight is typically administered. For certain conditions, repeated doses may be necessary, but this should be determined by a healthcare professional. It is important to take IVERZOOM on an empty stomach, preferably with water, to enhance absorption. Patients should follow the dosage instructions provided by their healthcare provider to ensure optimal efficacy and minimize the risk of side effects.

Interactions

IVERZOOM may interact with other medications, particularly those that affect the cytochrome P450 enzyme system. Drugs that induce or inhibit these enzymes may alter the metabolism of ivermectin, potentially leading to increased side effects or reduced efficacy. Concurrent use of IVERZOOM with other antiparasitic agents or medications that have central nervous system effects should be approached with caution. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Before starting treatment with IVERZOOM, a thorough medical history should be obtained, and any pre-existing conditions should be evaluated. Special caution is warranted in patients with a history of liver disease, as well as those with compromised immune systems or neurological disorders. During treatment, patients should be monitored for any signs of adverse reactions or worsening of their condition. Pregnant or breastfeeding women should consult their healthcare provider before using IVERZOOM, as the safety of ivermectin in these populations has not been fully established.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of IVERZOOM in treating various parasitic infections. In a randomized controlled trial involving patients with onchocerciasis, IVERZOOM was shown to significantly reduce the number of microfilariae in the skin and blood, leading to improved clinical outcomes. Another study focused on strongyloidiasis demonstrated that a single dose of IVERZOOM resulted in a high cure rate, with minimal adverse effects reported. These studies underscore the importance of IVERZOOM as a key therapeutic option in the management of parasitic infections.

Conclusion

IVERZOOM 12 MG is a valuable medication for the treatment of various parasitic infections, with a well-established mechanism of action and a favorable safety profile when used appropriately. Its efficacy has been supported by numerous clinical studies, making it a reliable choice for healthcare providers in managing these conditions. Patients should adhere to prescribed dosages and remain vigilant for any side effects, ensuring a successful treatment outcome.